Korea's Celltrion Develops Universal "Super Flu-Antibody Therapy"
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biopharma company Celltrion has developed a human monoclonal antibody product that could be effective against multiple influenza viruses such as the pandemic H1N1 and the H5N1 avian influenza virus